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Coronaviruses have caused at least three large scale epidemics/pandemics in humans over the 
past twenty years – severe acute respiratory syndrome (SARS) in 2003; the Middle East 
respiratory syndrome (MERS) in 2012; novel coronavirus disease (COVID-19) in 2019 – taking 
many lives all over the world. World Health Organization (WHO) named the new virus 
responsible for COVID-19 as SARS-CoV-2. 
 
For the SARS outbreak, the case-fatality rate was 11% while for MERS it was 34%. 1 According 
to Johns Hopkins University Coronavirus Resource Center, the case-fatality rate for COVID-19 
pandemic varies in reports from different countries. The mortality rate in the top ten most 
affected countries worldwide is between 4.5-16.3%. This virus is highly contagious and is 
responsible for taking more than 320,000 lives and affecting around 5 million people around the 
world, as of mid-May 2020. The mortality is almost twice higher in males compared to females. 
2 The White House Coronavirus Task Force estimated there will be between 100,000-240,000 
deaths due to COVID-19 in the US alone. Despite the implementation of many preventive 
policies all over the world i.e. social distancing, wearing masks etc., this virus is continuing to 
kill people, has taxed community health care centers, and therapeutic options are currently 
limited. 3 
 
There is an urgent need to better understand the pathophysiologic mechanism of the virus life 




This virus has a strong affinity toward angiotensin-converting enzyme 2 (ACE2) receptors in the 
respiratory system via S Protein on its envelope. S Protein is composed of one amino-terminal 
(S1) and one carboxy-terminal (S2). Cleavage at S1-S2 junction by protease is essential to 
activate membrane fusion. After binding, there are two different pathways through which the 
virus can enter the cell. First is the endosomal pathway which allows the virus entry at the 
plasma membrane. In the endosomal pathway, cathepsin [Cysteine protease] is responsible for 
the activation of membrane fusion and endocytosis. Low pH facilitates the endosomal cell entry 
in this path. Second is the non-endosomal pathway which allows the virus entry into the cell 
without endocytosis. In this pathway, TMPRSS2 [Serine protease] is needed to prime the spikes 
and allow the virus entry at the plasma membrane. After the virus enters the cell, in the next 
phase, the virus’s RNA replicates and eventually causes cell death. After cell death, the virus 
continues this cycle and infects other cells. 4,5 (Figure 1) 
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Figure 1: COVID-19 cell entry via the Non-Endosomal pathway. 
A host serine protease (TMPRSS2) is responsible for priming the spikes and allows the virus 
entry at the plasma membrane via the non-endosomal pathway. Cleavage at S1-S2 junction by 
TMPRSS2 activates membrane fusion. Bromhexine hydrochloride is shown to act as a 





Many medications have been used to interfere and block the virus cycle with different results. It 
has been proposed that chloroquine, by increasing the endosomal pH, may abrogate virus-
endosomal fusion and endocytosis, in addition to possibly exerting an antiviral effect inside the 
endosome. There is limited promising data about the efficacy of chloroquine or 
hydroxychloroquine in COVID-19. Amiodarone might be another effective agent in blocking 




Blocking the non-endosomal pathway might be an effective option to control COVID infection. 
The serine protease (TMPRSS2) could be a good target to prevent viral infection by blocking the 
fusion and priming the processes of the virus. 5 There are some medications such as camostat 
mesylate or nafamostat, which are used in chronic pancreatitis to inhibit the TMPRSS2 and 
eventually cell entry of SARS-COV-2. A trial using nafamostat is ongoing. No data is available 
now. 6 
 
TMPRSS2 is a member of the type II transmembrane serine protease (TTSP) family. TTMPRS2 
is expressed in the GI system, lungs, kidneys, and prostate. It has been shown that the presence 
of serine protease of TMPRSS2 is very essential for the influenza virus infection. This enzyme 
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cleaves the surface glycoprotein hemagglutinin (HA) of the influenza virus and ensues virus 
fusion and propagation. 7 The inhibition of TMPRSS2 by bromhexine can prevent influenza 
infection. 8 In addition to bromhexine, other synthetic inhibitors of TMPRSS2 have been 
developed and have demonstrated efficacy in preventing influenza infection. However, these 
inhibitors also have strong affinities for other proteases, such as matriptase, making their precise 
therapeutic mechanism unclear. 9 
 
TMPRSS2 expression in the prostate is driven by androgen receptor signaling. TMPRSS2 
mRNA expression is upregulated and remains elevated in androgen-stimulated prostate cancer. 
The administration of bromhexine hydrochloride, an inhibitor of TMPRSS2, was able to 
suppress distant metastasis to the liver and lungs sites in mice models via modulating of ERG 
oncogene. 10 This link between androgen receptor signaling and TMPRSS2 expression could 




Many antivirals, HIV medications, and steroids have been tried with no promising results in 
COVID-19, except limited clinical improvement in compassionate use of remedisivir which led 
to an emergency approval of medication by FDA but a multicenter, randomized, double-blind, 
placebo-controlled study did not show any significant clinical benefit. 12,13 
 
There is a debate about the role of angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin-receptor blockers (ARB) in COVID-19. The data showed that increasing the number 
of ACE2 receptors may not translate, as a rule, to getting the COVID-19 infection. It seems 




Many different medications have been tried to prevent, control or treat COVID-19 with 
debatable results. Bromhexine hydrochloride is an inexpensive and safe over-the-counter 
medication that has been used as a mucolytic since 1963 in clinical medicine. It increases the 
secretion of various mucous components and improves mucociliary clearance. 14 This medication 
can also inhibit TMPRSS2 and potentially prevent priming of the S-protein of coronavirus and 
abort the process of the virus entry into the cell. 15 
 
This idea has major public health importance and could change clinical practice or provide a 
novel approach to COVID-19 infection for clinicians, especially in underserved and rural areas 
with limited access to tertiary medical centers. The authors propose to use bromhexine 8 mg two 
or three times a day as a prophylactic/therapeutic measure during the COVID-19 pandemic. This 
monotherapy is safe and very inexpensive and therefore, most everybody can afford to get it. 
Further studies and clinical trials are needed to prove the validity of this medication therapy in 
COVID-19 infection. Multiple trials for bromhexine alone or in combination with 
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